Phase I study of the matrix metalloproteinase inhibitor, BAY 12-9566

C. Erlichman, A. A. Adjei, S. R. Alberts, J. A. Sloan, R. M. Goldberg, H. C. Pitot, J. Rubin, P. J. Atherton, G. G. Klee, R. Humphrey

Research output: Contribution to journalArticlepeer-review

70 Scopus citations


Background: Matrix metalloproteinases (MMPs) are involved in tumor invasion and metastasis and have been implicated in breast, ovarian, colorectal, and lung cancer growth. We undertook a phase I study of BAY 12-9566, an inhibitor of MMP-2, MMP-9, and MMP-3, in patients with solid tumors to determine its safety, pharmacokinetics, and effects on potential surrogate markers of biologic activity. Patients and methods: BAY 12-9566 was orally administered daily at four dose levels; 400 mg daily, 400 mg b.i.d., 400 mg t.i.d., and 800 mg b.i.d. Drug disposition was determined on days 1 and 29 with weekly trough levels measured during the first four weeks. Plasma vascular endothelial growth factor (VEGF), basic fibroblast growth factor (bFGF), and urinary pyridinoline and deoxypyridinoline crosslinks were determined at baseline, once weekly for four weeks, and then every four weeks. Results: Thirteen patients were entered on trial. BAY 12-9566 was well tolerated, with only one grade 3 headache, one grade 3 anemia, one grade 3 thrombocytopenia, and no musculoskeletal effects. The median treatment duration was 57 days (range 7-560). Mean trough levels of BAY 12-9566 on day 28 ranged from 80.5 to 108.6 mg/l. Plasma trough levels were 1500-42,000-fold above the Ki's for MMP-2, MMP-3, and MMP-9 at the 800 mg p.o. b.i.d. dose level. There was no significant change in VEGF, bFGF, pyridinoline, and deoxypyridinoline crosslinks with BAY 12-9566 administration. Conclusions: The recommended dose for further testing is 800 mg p.o. b.i.d.

Original languageEnglish (US)
Pages (from-to)389-395
Number of pages7
JournalAnnals of Oncology
Issue number3
StatePublished - 2001


  • Antimetastatic
  • Gelatinase A
  • Gelatinase B
  • Inhibitor
  • Matrixmetalloproteinase

ASJC Scopus subject areas

  • Hematology
  • Oncology


Dive into the research topics of 'Phase I study of the matrix metalloproteinase inhibitor, BAY 12-9566'. Together they form a unique fingerprint.

Cite this